On the Factors Modulating the Effect of Statins on Malignant Cell Proliferation

REFERENCES

• Farnier M., Davignon J. Current and future treatment of hyperlipidemia: the role of statins. Am. J. Cardiol. 1998; 82(43)3J–10J
   PubMedGoogle Scholar
• Denoyelle C., Vasse M., Körner M., Mishal Z., Ganné F., et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the intensiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 2001; 22(8)1139–1148
   PubMed Web of Science ®Google Scholar
• Shovman O., Levy Y., Gilburd B., Shoenfeld Y. Antiinflammatory and immunomodulatory properties of statins. Immunol. Res. 2002; 25(3)271–285
   PubMed Web of Science ®Google Scholar
• Li S., Koller R., Baghestanian M., Ghannadan M., Minar E., et al. Effect of statins on lipoprotein receptor expression in cell lines from human mast cells and basophils. Eur. J. Clin. Pharmacol. 2003; 59(7)507–516
   PubMed Web of Science ®Google Scholar
• Danesh F. R., Anel R. L., Zeng L., Lomasney J., Sahai A., Kanwar Y. S. Immunomodulatory effects of HMG-CoA reductase inhibitors. Arch. Immunol. Ther. Exp. (Warsz) 2003; 51(3)139–148
   PubMed Web of Science ®Google Scholar
• Cafforio P., Dammacco F., Gernone A., Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 2005; 26(5)883–891
   PubMed Web of Science ®Google Scholar
• Davignon J., Mabile L. Mechanisms of action of statins and their pleiotropic effects. Ann. Endocrinol. (Paris) 2001; 62: 101–112, (1 Pt. 2)
   PubMed Web of Science ®Google Scholar
• Sun D., Fernandes G. Lovastatin inhibits bone marrow-derived dendritic cell maturation and upregulates proinflammatory cytokine production. Cell Immunol. 2003; 223(1)52–63
   PubMed Web of Science ®Google Scholar
• Li H., Li X., Duan K., Li C. Inhibition of lovastatin on proliferation and expression of proinflammatory cytokines in cultured glomerular mesengial cells. Clin. Med. J. (Engl.) 2003; 116(9)1366–1369
   PubMed Web of Science ®Google Scholar
• Matsumoto M., Einhaus D., Gold E. S., Aderem A. Simvastatin augments lipopolysaccharide-induced proinflammatory responses in macrophages by differential regulation of the c-Fos and c-Jun transcription factors. J. Immunol. 2004; 172(12)7377–7384
   PubMed Web of Science ®Google Scholar
• Splichal J. E., Stam J. A., Ornstein D. L. The statins: multifunctional antithrombotic and antineoplastic drugs. Semin. Thromb. Hemost. 2003; 29(3)259–274
   PubMed Web of Science ®Google Scholar
• Etminan M., Gill S., Samii A. The role of lipid-lower drugs in cognitive function: a meta-analysis of observational studies. Pharmacotherapy 2003; 23(6)726–730
   PubMed Web of Science ®Google Scholar
• Friis S., Poulsen A. H., Johnsen S. P., McLaughlin J. K., Fryzek J. P., Dalton S. O., Sorenson H. T., Olsen J. H. Cancer risk among statin users: a population-based cohort study. Int. J. Cancer 2005; 114(4)643–647
   PubMed Web of Science ®Google Scholar
• Graaf M. R., Beiderbeck A. B., Egberts A. C., Richel D. J., Guchelaar H. J. The risk of cancer in users of statins. J. Clin. Oncol. 2004; 22(12)2388–2394
   PubMed Web of Science ®Google Scholar
• Graaf M. R., Richel D. J., van Noorden C. J., Guchelaar H. J. Effect of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat. Rev. 2004; 30(7)609–641
   PubMed Web of Science ®Google Scholar
• Sleijfer S., van der Gaast A., Planting A. S., Stoter G., Verweij J. The potential of statins as part of anti-cancer treatment. Eur. J. Cancer 2005; 41(4)516–522
   PubMed Web of Science ®Google Scholar
• Kozar K., Kaminski R., Legat M., Kopec M., Nowis D., Skierski J. S., Koronkiewicz M., Jakobisiak M., Golab J. Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. Int. J. Oncol. 2004; 24(5)1149–1157
   PubMed Web of Science ®Google Scholar
• Jakobisiak M., Golap J. Potential antitumor effect of statins (Review). Int. J. Oncol. 2003; 23(4)1055–1069
   PubMed Web of Science ®Google Scholar
• Kaye J. A., Jick H. Statin use and cancer risk in the General Practice Research Database. Br. J. Cancer 2004; 90(3)635–637
   PubMed Web of Science ®Google Scholar
• Hawk E., Viner J. L. Statins and cancer–beyond the “one drug, one disease” model. N. Eng. J. Med. 2005; 352(21)2238–2239
   PubMed Web of Science ®Google Scholar
• Duke R. C., Cohen J. J. Morphological and biochemical assays of apoptosis. Current Protocols in Immunology, J. E. Coligan, A. M. Kruisbeek, D. H. Marguilies, E. M. Shevach, W. Strober. Green/Wiley, New York 1992; 3.17.1, 17.16, Suppl. 3
   Google Scholar
• Seeger H., Wallwiener D., Mueck A. O. Statins can inhibit proliferation of human breast cancer cells in vitro. Exp. Clin. Endocrinol. Diabetes 2003; 111(1)47–48
   PubMed Web of Science ®Google Scholar
• Collisson E. A., Kleer C., Wu M., De A., Gambhir S. S., Merajver S. D., Kolodney M. S. Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol. Cancer. Ther. 2003; 2(10)941–948
   PubMed Web of Science ®Google Scholar
• Cauley J. A., Zmuda J. M., Lui L. Y., Hillier T. A., Ness R. B., Stone K. L., Cummings S. R., Bauer D. C. Lipid-lowering drug use and breast cancer in older women: a prospective analysis. Womens Health (Larchmt.) 2003; 12(8)749–756
   PubMed Web of Science ®Google Scholar
• Muck A. O., Seeger H., Wallwiener D. Inhibitory effect of statins on the proliferation of human breast cancer cells. Int. J. Clin. Pharmacol.Ther. 2004; 42(12)695–700
   PubMed Web of Science ®Google Scholar
• Poynter J. N., Gruber S. B., Higgins P. D., Almog R., Bonner J. D., et al. Statins and the risk of colorectal cancer. N. Eng. J. Med. 2005; 352(21)2238–2239
   PubMed Web of Science ®Google Scholar
• Paragh G., Foris G., Paragh G., Jr., Serez I., Karanyi Z., et al. Different anticancer effects of fluvastatin on primary hepatocellular tumors and metastases in rats. Cancer Lett. 2005; 222(1)17–22
   PubMed Web of Science ®Google Scholar
• Narisawa T., Fukaura Y., Terada K., Umezawa A., Tanida N., Yazawa K., Ishikawa C. Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice. Carcinogenesis 1994; 15(9)2045–2048
   PubMed Web of Science ®Google Scholar
• Dale K. M., Coleman C. I., Henyan N. N., Kluger J., White C. M. Statins and cancer risk: a meta-analysis. J.A.M.A. 2006; 295(1)74–80
   PubMed Web of Science ®Google Scholar
• Shepherd J., Blauw G. J., Murphy M. B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER); a randomised controlled trial. Lancet 2002; 360(9346)1623–1630
   PubMed Web of Science ®Google Scholar
• Kaushal V., Kohli M., Mehta P., Mehta J. L. Potential anticancer effects of statins: fact or fiction?. Endothelium 2003; 10(1)49–58
   PubMed Web of Science ®Google Scholar
• Ukomadu C., Dutta A. p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases. J Biol. Chem. 2003; 278(44)43586–43594
   PubMed Web of Science ®Google Scholar
• Newman A., Clutterbuck R. D., Powless R. L., Catovsky D., Millar J. L. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors. Leuk. Lymphoma 1997; 24(5–6)533–537
   PubMed Web of Science ®Google Scholar